Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacao Oswaldo CruzfiledCriticalFundacao Oswaldo Cruz
Priority to BR9804052-9ApriorityCriticalpatent/BR9804052A/pt
Publication of BR9804052ApublicationCriticalpatent/BR9804052A/pt
Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Medicinal Preparation
(AREA)
Abstract
"Suspensão Oral de Praziquantel". A presente invenção refere-se a uma composição farmacêutica para uso no tratamento da esquistossomose, especialmente desenvolvida para uso pediátrico e geriátrico, contendo grânulos de praziquantel revestidos ou microencapsulados com polímeros apropriados, para ser reconstituída e administrada sob a forma de uma suspensão oral de sabor agradável.
BR9804052-9A1998-10-231998-10-23Suspensão oral de praziquantel.
BR9804052A
(pt)
Novel substituted nitrocatechols, their use in the treatment of some central andperipheral nervous system disorders and pharmaceutical compositions containing them
The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
Tsüklopenteeni derivaadid, neid sisaldav farmatseutiline kompositsioon ning ühendite kasutamine ravimina inimestel esinevate motiliini retseptoriga seotud häirete raviks